Esposito Daina B, Desai Vibha C A, Stephenson Judith J, Cepeda M Soledad, Lyons Jennifer G, Holick Crystal N, Wedin Gregory P, Lanes Stephan
HealthCore, Inc., Wilmington, DE, USA.
Janssen Research and Development, Titusville, NJ, USA.
Patient Prefer Adherence. 2021 Feb 24;15:431-442. doi: 10.2147/PPA.S286935. eCollection 2021.
BACKGROUND/RATIONALE: The US Food and Drug Administration (FDA) approved a Risk Evaluation and Mitigation Strategy (REMS) for extended release/long-acting (ER/LA) opioids in 2012. The purpose of this study was to assess patient knowledge of the safe use of these products following implementation of the REMS and to determine possible effects of the REMS, including impact on medication access.
To assess patient knowledge of safe use of ER/LA opioids and use of REMS patient education tools such as the Medication Guide (MG) and Patient Counseling Document (PCD).
This was a cross-sectional survey of commercially insured (Commercial) and Medicare Advantage-insured (Medicare) adults with ≥1 pharmacy claim for an ER/LA opioid (10/01/2015 - 02/28/2017) in the HealthCore Integrated Research Database and Medicaid-insured (Medicaid) adult members of a research panel, about their knowledge of safe use of ER/LA opioids and receipt/comprehension of the MG and PCD.
Survey respondents consisted of 382 Commercial, 43 Medicare and 40 Medicaid adults. While ≥95% of respondents received and read the MG, fewer were aware of the PCD (Commercial: 47%, Medicare: 65%, Medicaid: 53%). Almost 75% of the knowledge questions were answered correctly by ≥80% of all respondents; fewer respondents recognized that use of opioids as directed can lead to death (Commercial: 73%, Medicare: 56%, Medicaid: 63%), the MG should be read at each dispensing (Commercial: 78%, Medicare: 53%, Medicaid: 75%), opioids should not be stored in the medicine cabinet (Commercial: 77%, Medicare: 79%, Medicaid: 58%), missed doses should not be taken as soon as possible (Commercial: 56%, Medicare: 51%, Medicaid: 50%), and pills should not be crushed (Commercial: 85%, Medicare: 67%, Medicaid: 52%).
Although most respondents reported reading and understanding the MG and exhibited knowledge of safe use of ER/LA opioids, providers' use of the PCD and increased understanding of safe use core messages need reinforcement.
背景/基本原理:美国食品药品监督管理局(FDA)于2012年批准了一项针对缓释/长效(ER/LA)阿片类药物的风险评估与缓解策略(REMS)。本研究的目的是评估在实施REMS后患者对这些产品安全使用的了解情况,并确定REMS的可能影响,包括对药物可及性的影响。
评估患者对ER/LA阿片类药物安全使用的了解情况以及对REMS患者教育工具(如用药指南(MG)和患者咨询文件(PCD))的使用情况。
这是一项横断面调查,研究对象为在HealthCore综合研究数据库中有≥1次ER/LA阿片类药物(2015年10月1日至2017年2月28日)药房配药记录的商业保险(Commercial)和医疗保险优势计划保险(Medicare)的成年人,以及一个研究小组中医疗补助保险(Medicaid)的成年成员,调查他们对ER/LA阿片类药物安全使用的了解情况以及对MG和PCD的接收/理解情况。
调查对象包括382名商业保险成年人、43名医疗保险成年人和40名医疗补助保险成年人。虽然≥95%的受访者收到并阅读了MG,但知晓PCD的受访者较少(商业保险:47%,医疗保险:65%,医疗补助保险:53%)。几乎75%的知识问题有≥80%的受访者回答正确;较少受访者认识到按指示使用阿片类药物可能导致死亡(商业保险:73%,医疗保险:56%,医疗补助保险:63%)、每次配药时都应阅读MG(商业保险:78%,医疗保险:53%,医疗补助保险:75%)、阿片类药物不应存放在药柜中(商业保险:77%,医疗保险:79%,医疗补助保险:58%)、漏服剂量不应尽快补服(商业保险:56%,医疗保险:51%,医疗补助保险:50%)以及药片不应碾碎(商业保险:85%,医疗保险:67%,医疗补助保险:52%)。
虽然大多数受访者报告阅读并理解了MG,且表现出对ER/LA阿片类药物安全使用的了解,但仍需加强医疗服务提供者对PCD的使用以及对安全使用核心信息的理解。